BioNTech, Regeneron claim Phase 2 win for cancer vaccine, PD-1 combo
One of BioNTech’s first mRNA cancer vaccine candidates has cleared a key mid-stage trial, setting it up for a potential showdown with a closely-watched and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.